Otsuka stock holds after FY2025 sales and profit growth

Otsuka stock is anchored by FY2025 results that showed JPY 2,329.5 billion in sales and JPY 330.5 billion in operating profit for Otsuka Holdings Co., Ltd. (JP3200450009). The company also reported JPY 255.5 billion in profit attributable to owners of the parent for the year ended 31 December 2025, giving investors a concrete earnings base to assess against the current share price.

FY2025 sales up 19.7%

Otsuka said annual sales rose 19.7% from the previous year, while operating profit increased 99.4% year on year. Those two comparisons matter more than any broad company description because they show that FY2025 growth was not limited to revenue alone; profitability expanded faster than the top line.

The balance sheet also remained central to the story. As of 31 December 2025, Otsuka reported total assets of JPY 4,627.1 billion and equity of JPY 2,819.4 billion, which places the group on a sizeable capital base heading into 2026.

Profit nearly doubled

Operating profit of JPY 330.5 billion and profit attributable to owners of the parent of JPY 255.5 billion are the two numbers that define the latest earnings picture. The 99.4% increase in operating profit is the sharpest quantified change in the latest annual set and gives the stock a clearer valuation reference than a generic outlook statement.

Cash generation also stayed visible in the year-end numbers. Otsuka reported JPY 336.6 billion in net cash provided by operating activities for FY2025, compared with JPY 200.7 billion in the prior year, which is a useful sign that profit growth was backed by real operating cash flow.

Portfolio still matters

Otsuka Holdings is still led by its healthcare and pharmaceutical franchise, with products such as Abilify, Rexulti, and Samsca remaining part of the companys commercial profile. Those brands matter because the annual results are not just a financial snapshot; they also reflect the contribution of branded medicines that can move revenue, margin, and cash flow together.

The company also reported total liabilities of JPY 1,807.7 billion as of 31 December 2025, against equity of JPY 2,819.4 billion. That ratio gives the stock another way to be read by market participants: the latest annual figures show growth without a balance-sheet stretch that would dominate the earnings discussion.

Market value reference

Otsuka stock can be viewed against the latest annual report context rather than a single-day catalyst. The FY2025 sales base of JPY 2,329.5 billion, operating profit of JPY 330.5 billion, and net cash from operations of JPY 336.6 billion define the current reference point for the shares.

For investors tracking the name into the next earnings cycle, the most important question is whether the company can sustain the 19.7% sales growth rate and the 99.4% operating-profit increase that it posted for FY2025. The annual numbers already show that Otsuka enters the next period with both scale and improved profitability.

Rexulti remains key

Rexulti remains one of the best-known products in the Otsuka portfolio and helps explain why the company can still post large-group revenue. In a business where product concentration and lifecycle management matter, the durability of core medicines often matters more to the share price than any single quarterly headline.

That product backdrop is relevant because Otsuka's FY2025 performance was not a one-line headline story; it was a year in which sales, profit, and cash flow all moved higher at the same time. The stock therefore reads less like a pure momentum name and more like a large-cap healthcare compounder with a detailed operating base.

FY2025 sets the frame

The final market reference comes from the annual numbers themselves. Sales of JPY 2,329.5 billion, operating profit of JPY 330.5 billion, and profit attributable to owners of the parent of JPY 255.5 billion are the clearest figures to carry into any valuation discussion, and all three are fully periodized for FY2025.

Otsuka stock is therefore best read through the lens of FY2025 rather than a short-term narrative. The companys latest annual report gives the shares a quantifiable base: higher sales, nearly doubled operating profit, and operating cash flow that also increased year on year.